Active Litigation, Accepting Clients

People who suffered kidney or bone injuries after taking TDF-based HIV medications may qualify for a free case review.

DefendantGilead Sciences
MDLCoordinated litigation (no MDL)
CourtN.D. Cal. and California state court (JCCP)
Filing DeadlineVaries by state; deadlines often run from when you connected your injury to the medication.

Get a Free Case Review

Truvada Lawsuit

Truvada, Viread, Atripla, Complera, and Stribild are HIV treatment and prevention medications made by Gilead Sciences that contain tenofovir disoproxil fumarate (TDF). Since 2001, millions of people have relied on TDF drugs — many taking them daily for years or decades, because consistent use is essential to controlling or preventing HIV.

Why Are Truvada and TDF Lawsuits Being Filed?

Plaintiffs allege two things. First, that TDF is toxic to the kidneys and bones at its approved dose, causing chronic kidney disease, kidney failure, Fanconi syndrome, and bone density loss leading to osteoporosis and fractures — and that Gilead failed to adequately warn. Second, and central to the litigation, that Gilead developed a safer alternative — tenofovir alafenamide (TAF), which delivers effective treatment at a fraction of the dose with less kidney and bone toxicity — years earlier, but shelved it until TDF’s patent protection was running out. Gilead denies the allegations.

Where the Litigation Stands

TDF litigation is coordinated primarily in California — in federal court in the Northern District of California and in a coordinated state court proceeding — involving thousands of plaintiffs nationwide, rather than a traditional MDL. In 2024, Gilead reached an agreement in principle to pay $40 million to resolve roughly 2,625 federal cases. A pivotal appeal is now before the California Supreme Court on whether Gilead can be held liable for delaying the safer TAF drugs; briefing continued into 2026, and the court’s decision is expected to shape the remaining litigation. Attorneys continue to evaluate new TDF claims.

Injuries in the TDF Litigation

Chronic kidney disease, kidney failure requiring dialysis or transplant, Fanconi syndrome, osteopenia, osteoporosis, osteomalacia, and bone fractures — in people who took TDF-based medications, often for years.

Who May Qualify?

You may qualify for a free case review if you took Truvada, Viread, Atripla, Complera, Stribild, or a generic TDF medication and were diagnosed with kidney disease, kidney failure, Fanconi syndrome, or significant bone density loss or fractures. Prescription history and the medical records documenting your diagnosis are the core evidence.

Important: Never stop an HIV treatment or prevention medication without talking to your doctor. Safer alternatives exist, and your care team can help you switch safely if appropriate.

Injuries Linked to This Litigation

  • Chronic kidney disease and kidney failure
  • Fanconi syndrome
  • Bone density loss (osteopenia, osteoporosis)
  • Bone fractures

Do You Qualify?

Took Truvada, Viread, Atripla, Complera, Stribild, or a generic TDF medication
Diagnosed with kidney disease, kidney failure, Fanconi syndrome, or significant bone density loss or fractures

Get a Free Case Review

Name(Required)
Which product were you exposed to, and what injury or diagnosis followed?
Consent(Required)

Attorney Advertising. Prior results do not guarantee a similar outcome. Submitting a form does not create an attorney client relationship.